Medigene AG Medigene AG

Medigene AG

MDG1

Classement en actions #35337
Medigene AG is a German biotechnology company primarily focused on innovating T... Medigene AG is a German biotechnology company primarily focused on innovating T cell immunotherapies to treat various cancers. Their developmental pipeline includes personalized T cell therapies, particularly T cell receptor-modified T cells, which are progressing through clinical stages to tackle significant unmet medical requirements. Additionally, the firm researches dendritic cell vaccines and T cell-specific monoclonal antibodies. Outside of its oncology efforts, Medigene is actively engaged in developing and bringing to market RhuDex for uses within hepatology and gastroenterology. A key strategic alliance exists with 2seventy bio, Inc., centered on advancing T cell receptors. The company also maintains research collaborations with the Université de Montréal and Cytovant Sciences Co. Ltd., investigating new cancer antigens for immunotherapy applications. Medigene's global presence encompasses operations across Europe, the United States, Asia, and various other international territories. Founded in 1994, the company's headquarters are located in Munich, Germany.
Prix de l'action
$0.14942078
Dernière synchronisation: 2025-05-15
Capitalisation boursière
$3.86M
Changement (1 jour)
0.10%
Changement (1 an)
39.97%
Pays
DE
Échange Medigene AG (MDG1)

Catégorie

Healthcare
EPS pour Medigene AG (MDG1)
EPS au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Medigene AG, l’EPS actuel de la société (TTM) est de 0. À la fin de 2026, la société avait un EPS de 0 égal à celui de 2026, qui était de 0.
Historique de l'EPS de Medigene AG de 2026 à 2026
EPS à la fin de chaque année
Année EPS Changez
Pas assez de données pour les dates fournies.
EPS pour des entreprises ou concurrents similaires
Entreprise EPS Différence d’EPS Pays
$17.32 -
US
$-7.98 -
US
$-5.29 -
AU
- -
CH
$27.74 -
NL